{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T22:31:43Z","timestamp":1783722703049,"version":"3.55.0"},"reference-count":18,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2015,3,28]],"date-time":"2015-03-28T00:00:00Z","timestamp":1427500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The high cost, coupled with the need for continuous infusion, renders Desferrioxamine (DFO), a non\u2010feasible option for iron\u2010chelation in a large majority of patients with \u03b2\u2010thalassemia major in developing countries. Monotherapy with deferiprone (DFP) or deferasirox (DFX) may not always attain optimal control, particularly in heavily iron\u2010loaded patients. Combination of DFP and DFX is a potential alternative.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>A prospective, single\u2010center, open\u2010label, uncontrolled study was conducted to evaluate the safety and efficacy of the combination in patients with \u03b2\u2010thalassemia major. Patients who had received either DFP or DFX for &gt;1 year and a serum ferritin &gt;2,000\u2009\u03bcg\/L were enrolled. Blood counts, liver\/renal functions, and serum ferritin were monitored during the 1\u2010year study period. Facilities for cardiac T2*\u2010MRI were unavailable.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty\u2010six patients with a mean age of 13 \u00b1 6.9 years (range: 4\u201329) and a ferritin of 6,768 \u00b1 4,145\u2009\u03bcg\/L formed the study cohort. Eight (22%) patients had transient gastrointestinal adverse effects. DFX was discontinued in one patient for persistent abdominal pain\/diarrhea. Eight (22%) had joint symptoms; DFP was discontinued in two. Four (11%) patients had elevation in AST\/ALT levels, managed with temporary interruption of DFX. Nine (25%) had an inconsistent elevation of creatinine to &gt;33% of baseline; no intervention was done. One had transient proteinuria. None had neutropenia. At the end of 1 year, the serum ferritin reduced by a mean value of 3,275.3 \u00b1 618.2\u2009\u03bcg\/L (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The oral combination was found to be safe, efficacious, and a feasible option in patients with suboptimal response to monotherapy. Pediatr Blood Cancer 2015;62:1592\u20131596. \u00a9 2015 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.25533","type":"journal-article","created":{"date-parts":[[2015,3,29]],"date-time":"2015-03-29T06:38:27Z","timestamp":1427611107000},"page":"1592-1596","source":"Crossref","is-referenced-by-count":47,"title":["The deferiprone and deferasirox combination is efficacious in iron overloaded patients with \u03b2\u2010thalassemia major: A prospective, single center, open\u2010label study"],"prefix":"10.1002","volume":"62","author":[{"given":"Sidharth","family":"Totadri","sequence":"first","affiliation":[{"name":"Department of Pediatrics Hematology\u2013Oncology Unit and Biochemistry Advanced Pediatric Center Post Graduate Institute of Medical Education and Research Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Bansal","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Hematology\u2013Oncology Unit and Biochemistry Advanced Pediatric Center Post Graduate Institute of Medical Education and Research Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prateek","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Hematology\u2013Oncology Unit and Biochemistry Advanced Pediatric Center Post Graduate Institute of Medical Education and Research Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savita V.","family":"Attri","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Hematology\u2013Oncology Unit and Biochemistry Advanced Pediatric Center Post Graduate Institute of Medical Education and Research Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Trehan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Hematology\u2013Oncology Unit and Biochemistry Advanced Pediatric Center Post Graduate Institute of Medical Education and Research Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. K.","family":"Marwaha","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Hematology\u2013Oncology Unit and Biochemistry Advanced Pediatric Center Post Graduate Institute of Medical Education and Research Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,3,28]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S13065"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2012.03580.x"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.3109\/03630260903346924"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-010-0933-1"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21711"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2011.03.007"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08626.x"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12507"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000345734"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.014696"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3430"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3280"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03554.x"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02724272"},{"key":"e_1_2_5_16_1","first-page":"1343","article-title":"Phase II clinical evaluation of deferasirox, a once\u2010daily oral chelating agent, in pediatric patients with beta\u2010thalassemia major","volume":"91","author":"Galanello R","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23386"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.2003.00325.x"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.3109\/03630260903346676"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.25533","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.25533","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T05:22:44Z","timestamp":1696396964000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.25533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,28]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.1002\/pbc.25533"],"URL":"https:\/\/doi.org\/10.1002\/pbc.25533","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,28]]}}}